Skip to content

The Oral Microbiome in OSCC

The Oral Microbiome in Oral Squamous Cell Carcinoma

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04925700
Enrollment
20
Registered
2021-06-14
Start date
2022-04-20
Completion date
2023-10-10
Last updated
2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Cancer

Brief summary

Previous work by a number of scientific teams has revealed that the types of bacteria that colonize the mouth differ between health and pre-cancerous or cancerous oral lesions. The purpose of this study is to investigate the extent of these changes and to correlate the changes with alterations in the activities of the host's own oral tissues. In doing so, we believe we can gain a better understanding of how particular bacterial species, or consortia of species, can result in an individual having an increased risk of the most common type of oral cancer -- oral squamous cell carcinoma. This knowledge may also lead to the identification of salivary biomarkers that can be used for clinical evaluation or screening. In addition, we seek to determine the extent to which a probiotic regimen can help prevent or rectify the disease-related changes in the types of bacterial colonizing the mouth. The microbiome in health, pre-cancerous lesions, and cancerous lesions will be determined from remnant microbial DNA in banked tissue samples. The effects of probiotics on the oral microbiome will be determined from DNA collected from swabs of oral tissue at baseline and then after 3 to 6 months of probiotic usage.

Interventions

DIETARY_SUPPLEMENTProDentis Lozenge

1-2 ProDentis Lozenges per day

1-2 Placebo Lozenges per day

Sponsors

University of Iowa
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

1. Adults (21-70 years old) who have been diagnosed with oral dysplasia or that have been treatment-planned as wait and watch or 2. Adults (21-70 years old) or who have been diagnosed with oral squamous cell carcinoma, or matched healthy controls free of any oral lesions

Exclusion criteria

1. Adults who have had a course of antibiotics that was completed less than 3 months prior to the study; 2. Adults with any immunosuppressive condition or medication that would put the subject at risk of consuming daily probiotics; 3. Adults who regularly use probiotic dietary supplements 4. Adults that have alcohol/tobacco use history that does not match study population - this if for the healthy controls arm only.

Design outcomes

Primary

MeasureTime frameDescription
Assessment of changes in the oral microbiome composition over timeUp to 3 months16S Genomic Profiling will be done in all recruited subjects via oral swab of pre-cancerous or cancerous oral lesion
Determine the Effect of ProDentis on the Oral MicrobiomeUp to 3 monthsPre-Cancerous lesion is treatment planned as watch-and-wait or oral lesion is not present, recruited subjects will be randomly assigned to either the probiotic lozenge or placebo lozenge group.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026